Literature DB >> 27371395

Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS.

Rohit Bisht1, Abhirup Mandal2, Ilva D Rupenthal1, Ashim K Mitra3.   

Abstract

This study aimed to develop and evaluate an ex vivo eye model for intravitreal drug sampling and tissue distribution of connexin43 mimetic peptide (Cx43MP) following intravitreal injection using the microdialysis technique and LC-MS/MS. An LC-MS/MS method was developed, validated, and applied for quantification of Cx43MP in ocular tissues. Microdialysis probes were calibrated for in vitro recovery studies. Bovine eyes were fixed in a customized eye holder and after intravitreal injection of Cx43MP, microdialysis probes were implanted in the vitreous body. Vitreous samples were collected at particular time intervals over 24 h. Moreover, 24 and 48 h after intravitreal injection ocular tissues were collected, processed, and analyzed for Cx43MP concentrations using LC-MS/MS. The LC-MS/MS method showed good linearity (r 2 = 0.9991). The mean percent recovery for lower (LQC), medium (MQC), and higher quality control (HQC) (0.244, 3.906, and 125 μg/mL) was found to be 83.83, 84.92, and 94.52, respectively, with accuracy ranges between 96 and 99 % and limits of detection (LOD) and quantification (LOQ) of 0.122 and 0.412 μg/mL. The in vitro recovery of the probes was found to be over 80 %. As per microdialysis sample analysis, the Cx43MP concentration was found to increase slowly in the vitreous body up to 16 h and thereafter declined. After 48 h, the Cx43MP concentration was higher in vitreous, cornea, and retina compared to lens, iris, and aqueous humor. This ex vivo model may therefore be a useful tool to investigate intravitreal kinetics and ocular disposition of therapeutic molecules after intravitreal injection.

Entities:  

Keywords:  Bovine eyes; Cx43MP; Ex-vivo intraocular model; Ocular drug delivery; Tissue distribution; Vitreo-retinal diseases

Mesh:

Substances:

Year:  2016        PMID: 27371395     DOI: 10.1007/s13346-016-0308-9

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  30 in total

Review 1.  Drug delivery for posterior segment eye disease.

Authors:  D H Geroski; H F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-04       Impact factor: 4.799

Review 2.  Modern drug delivery systems for targeting the posterior segment of the eye.

Authors:  Catalina A Peptu; Marcel Popa; Corina Savin; Radu F Popa; Lacramioara Ochiuz
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

3.  Poiseuille's law and large-bore needles: insights into the delivery of corticosteroid injections in the treatment of keloids.

Authors:  Gary S Chuang; Gary S Rogers; Ross Zeltser
Journal:  J Am Acad Dermatol       Date:  2008-07       Impact factor: 11.527

4.  Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume.

Authors:  S Friedrich; Y L Cheng; B Saville
Journal:  Curr Eye Res       Date:  1997-07       Impact factor: 2.424

5.  Ischemia-induced brain damage depends on specific gap-junctional coupling.

Authors:  Marina V Frantseva; Larisa Kokarovtseva; Jose L Perez Velazquez
Journal:  J Cereb Blood Flow Metab       Date:  2002-04       Impact factor: 6.200

6.  Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique.

Authors:  P M Hughes; R Krishnamoorthy; A K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  1996       Impact factor: 2.671

7.  In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits.

Authors:  Banmeet S Anand; Suresh Katragadda; Sriram Gunda; Ashim K Mitra
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

8.  Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.

Authors:  Ron A Adelman; Qi Zheng; Hylton R Mayer
Journal:  J Ocul Pharmacol Ther       Date:  2010-02       Impact factor: 2.671

9.  Ocular pharmacokinetics of cephalosporins using microdialysis.

Authors:  S Macha; A K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2001-10       Impact factor: 2.671

10.  Posterior segment ocular pharmacokinetics using microdialysis in a conscious rabbit model.

Authors:  Clapton S Dias; Ashim K Mitra
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.